11 results about "Ganglion" patented technology

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

In some embodiments, disclosed herein are systems and methods of treating a patient that can include the steps of accessing the sphenopalatine fossa, and cannulating the inferior orbital fissure from the sphenopalatine fossa to access the retro-orbital space. The sphenopalatine fossa can be accessed via various routes, including percutaneously. Accessing the sphenopalatine fossa can include the step of inserting a needle-catheter system into the sphenopalatine fossa. Integrated needle-catheter systems as described herein can also be configured to access the trigeminal ganglion, epidural space, intrathecal space, and other desired anatomical locations.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The application provides an application of YAP in preparation of a drug for preventing or treating retinal ganglion cell injury, and proves that up-regulation of YAP expression or activity can significantly reduce the retinal oxidative stress level, inhibit the neuroinflammatory response, and reduce the number of RGC death, thereby effectively protecting the nerve function. The application provides a new treatment target for diseases characterized by RGC injury, such as traumatic optic neuropathy and glaucoma, and YAP or an expression promoter thereof can be used for preparing a drug for preventing, relieving and / or treating the diseases, and has an important clinical application prospect.

This invention relates to the field of novel pharmaceutical uses, disclosing the application of methyl jasmonate in the preparation of drugs for delaying age-related hearing loss. This invention is the first to clearly discover that methyl jasmonate can significantly improve the auditory function of aged mice, significantly enhance the pure tone hearing threshold and speech recognition ability of aged mice, effectively protect the structural integrity of the cochlea, reduce apoptosis of cochlear hair cells and spiral ganglion cells, inhibit the inflammatory response and oxidative stress damage of the auditory system, and delay the degenerative process of the auditory system from a pathological perspective, which has important clinical translational potential and market value.

The application belongs to the technical field of biological medicine, and discloses application of plerixafor in preparation of a medicine for treating traumatic optic neuropathy. Researches of the application show that the plerixafor has a repairing effect of promoting survival of retinal ganglion cells (RGC) and axon regeneration after optic nerve injury, and can achieve and improve the effect of treating traumatic optic nerve injury.

This application relates to ophthalmic lenses for use in the eye. The ophthalmic lens includes an anterior surface, a posterior surface, an optical center, and an optical region surrounding the optical center. The optical region includes a basic prescription for the eye and multiple non-refractive features; wherein the basic prescription includes spherical correction, astigmatism correction, or spherical and astigmatism correction. The non-refractive features contribute to increased retinal ganglion cell activity in the wearer, which can serve as an optical stopping signal to slow, improve, control, inhibit, or reduce the rate of myopia progression in the wearer.

This invention relates to the field of biomedicine, specifically to a liposome-exosome hybrid vesicle loaded with ciliary neurotrophic factor (CNTF), its preparation method, and its application. This multifunctional hybrid vesicle comprises human umbilical cord mesenchymal stem cell exosomes and liposomes, with a particle number ratio of 1-4:1-4 for the human umbilical cord mesenchymal stem cell exosomes to liposomes. It is an innovative delivery system with dual functions, retaining the inherent natural targeting and biocompatibility of exosomes while integrating the efficient encapsulation and protection capabilities of liposomes for CNTF. In application, this multifunctional hybrid vesicle is used in a treatment model of traumatic optic nerve injury. This system can deliver bioactive CNTF to the injury site, effectively promoting the survival of retinal ganglion cells and axonal regeneration, demonstrating excellent therapeutic effects and providing a highly promising strategy for the treatment of central nervous system diseases such as optic nerve injury.

This invention discloses an exosome-like nanovesicle derived from Hangzhou white chrysanthemum, its preparation method, and its application in the treatment of optic nerve and retinal degenerative diseases. In vitro experiments show that the exosome-like nanovesicles derived from Hangzhou white chrysanthemum provided by this invention can effectively inhibit glutamate-induced oxidative stress and mitochondrial damage in retinal cells, and enhance cell viability. In vivo experiments show that intravitreal injection of these exosome-like nanovesicles derived from Hangzhou white chrysanthemum can significantly improve the survival rate of ganglion cells in the retina of mice with NMDA damage and improve their visual electrophysiological function. This invention provides a new approach and method for the treatment of optic nerve and retinal degenerative diseases, and has broad application prospects. Furthermore, the preparation method of the exosome-like nanovesicles derived from Hangzhou white chrysanthemum provided by this invention is simple and has advantages such as low cost, wide applicability, good safety, and absence of animal-derived components.

This invention discloses a method for constructing an inducible CaMKIIα-initiated cell line and its applications. The inducible CaMKIIα-initiated cell line is obtained by knocking in the DNA sequence shown in SEQ ID No. 2 (positions 861-5336 from the 5' end) into the AAVS1 safe harbor site of the human embryonic stem cell genome. Based on a strategy combining the Tet-on system and the CRISPR / Cas9 system, this invention constructs a cell line in hESCs where tetracycline controls the CaMKIIα phosphorylation switch. This method is precise, controllable, stable, and low-cost, and is of great significance for studying CaMKIIα function. Using this cell line, it was found that initiating CaMKIIα can promote axonal regeneration in ganglion cells. This invention provides a useful tool for studying the pathogenesis and treatment of nervous system diseases and has significant application value.